PartnersPublications Resources Consensus ViewpointsInteractive ToolsSponsored Biomarker ConsortiumSubscribe Choose Specialty Biosimilars Brain Cancer Breast CancerBreast Cancer CAR T-cell Therapy COVID-19 Disparities in Cancer Care Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGas...
Other serious side effects include pneumonia and other severe infections, but these are less common. Another possible side effect is TLS. Combination therapy Many people with CLL get a combination of therapies that can include chemotherapy, targeted therapy, and monoclonal antibodies. An example of ...
Of the 691 patients in GALLIUM treated with GAZYVA plus chemotherapy as first-line therapy, 33% were 65 and over, while 7% were 75 and over. Of patients 65 and over, 63% experienced serious adverse reactions and 26% experienced adverse reactions leading to treatment withdrawal, while in patie...
Targeted Therapy:Venetoclax API's targeted mechanism of action allows it to specifically inhibit BCL-2 proteins, effectively targeting CLL cells while sparing healthy cells. This targeted approach enhances the drug's clinical efficacy, reducing the burden of chemotherapy-related side effect...
With idelalisib, after many months of therapy, one out of seven patients may develop colitis, similar to an inflammatory bowel disease. So what we are seeing is although there cancer is improved, we are seeing this autoimmune disease that we have to recognize so we can stop therapy and ...
Adults and children 1 year of age and older with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy. It is not known if IMBRUVICA® is safe and effective in children under 1 year of age. ...
Adults and children 1 year of age and older with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy. It is not known if IMBRUVICA® is safe and effective in children under 1 year of age. ...
Infections: Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of Rituxan-based therapy. Withhold Rituxan and institute appropriate anti-infective therapy. Rituxan is not recommended for use in patients with severe, active ...
single agent therapyvenetoclaxContext Venetoclax side effects and toxicity are now well known, and most UK services have adopted the conservative approach of monthly prescriptions throughout therapy. Design We retrospectively reviewed data from patients who received treatment with venetoclax therapy either ...
Once you do start treatment, it won't have an end date. CLL usually can't be cured with a few rounds of chemo or targeted therapy. It's a chronic, or lifelong, disease. You'll learn to manage your cancer and its symptoms throughout your life. You might say that life with CLL is...